P-Selectin Glycoprotein Ligand 1: A Potential HIV-1 Therapeutic Target

Silvère D. Zaongo, Yanqiu Liu, Vijay Harypursat, Fangzhou Song, Huan Xia, Ping Ma, Yaokai ChenFrontiers in Immunology 2021 · DOI

Abstract

Antiretroviral therapy (ART), which is a life-long therapeutic option, remains the only currently effective clinical method to treat HIV-1 infection. However, ART may be toxic to vital organs including the liver, brain, heart, and kidneys, and may result in systemic complications. In this context, to consider HIV-1 restriction factors from the innate immune system to explore novel HIV therapeutics is likely to be a promising investigative strategy. In light of this, P-selectin glycoprotein ligand 1 (PSGL-1) has recently become the object of close scrutiny as a recognized cell adhesion molecule, and has become a major focus of academic study, as researchers believe that PSGL-1 may represent a novel area of interest in the research inquiry into the field of immune checkpoint inhibition. In this article, we review PSGL-1's structure and functions during infection and/or inflammation. We also outline a comprehensive review of its role and potential therapeutic utility during HIV-1 infection as published in contemporary academic literature.

Introduction: The Need for New HIV-1 Strategies

While Antiretroviral Therapy (ART) has successfully transformed HIV-1 into a manageable chronic condition, it falls short of being a cure. Patients face a lifetime of adherence and potential long-term toxicity affecting the liver, brain, and kidneys. Furthermore, the persistence of viral "reservoirs" remains a significant barrier to eradication. Consequently, researchers are turning to the innate immune system to identify "restriction factors"—host proteins that naturally impede the viral life cycle.

The Traditional Role of PSGL-1

P-selectin glycoprotein ligand 1 (PSGL-1) is traditionally recognized for its critical role in the inflammatory response. It acts as a cell adhesion molecule that facilitates the "rolling" and "tethering" of white blood cells along the endothelial walls of blood vessels, eventually allowing them to exit the bloodstream and enter sites of inflammation (extravasation).

PSGL-1 mediates T cell rolling and extravasation during inflammation.

PSGL-1 as a Potent HIV-1 Restriction Factor

Recent evidence has identified PSGL-1 as a multi-functional host protein that acts as a potent innate restriction factor against HIV-1. It operates through a dual-stage inhibition mechanism:

  1. Early-Stage Blockade: PSGL-1 binds to the cell's actin cytoskeleton, physically obstructing the viral reverse transcription complex and preventing the synthesis of viral DNA. This effect is highly dependent on the PSGL-1 cytoplasmic tail; mutations at specific residues, such as Threonine 393 (T393), can abolish this antiviral activity.
  2. Late-Stage Inactivation: During the budding process, PSGL-1 is incorporated into new virions. Its presence physically crowds out essential viral Envelope (Env) proteins (gp120 and gp41), resulting in "bald," non-infectious virus particles.
PSGL-1 interferes with the HIV-1 life cycle by producing membrane-defective, non-infectious particles.

The significance of PSGL-1 is further highlighted by the viral counter-attack: HIV-1 has evolved specific proteins, Vpu and Nef, to degrade or sequester PSGL-1, illustrating an ongoing evolutionary "arms race."

Clinical Observations and Key Results

Literature reviews of clinical cohorts reveal that PSGL-1 expression on monocytes is significantly decreased in patients with primary HIV infection (PHI) compared to healthy controls. While levels may partially recover during chronic infection, they rarely return to baseline. In vitro studies demonstrate that even modest overexpression of PSGL-1 can significantly inhibit virion infectivity, often more effectively than its ability to block DNA synthesis. Furthermore, PSGL-1 expression can be induced ex vivo using cytokines like interferon-gamma (IFN-γ), suggesting potential therapeutic pathways.

Limitations and Future Directions

Despite its promise, several hurdles remain for PSGL-1-based therapies:

  • Immune Exhaustion: PSGL-1 also functions as an immune checkpoint (similar to PD-1). Simply upregulating it might inadvertently promote T-cell exhaustion, necessitating a strategy to decouple its antiviral properties from its inhibitory signaling.
  • Clade Specificity: It is unclear if PSGL-1 is equally effective against all HIV-1 strains.
  • Safety and Delivery: Inducing PSGL-1 systemically could risk a "cytokine storm" or chronic inflammation.
  • "Shock and Kill": While PSGL-1 signaling might help "shock" latent viruses out of hiding, results have been inconsistent across different cell types.

Future research must focus on safely leveraging this host defense without triggering systemic complications or immune dampening.

Summary updated

Abstract

Antiretroviral therapy (ART), which is a life-long therapeutic option, remains the only currently effective clinical method to treat HIV-1 infection. However, ART may be toxic to vital organs including the liver, brain, heart, and kidneys, and may result in systemic complications. In this context, to consider HIV-1 restriction factors from the innate immune system to explore novel HIV therapeutics is likely to be a promising investigative strategy. In light of this, P-selectin glycoprotein ligand 1 (PSGL-1) has recently become the object of close scrutiny as a recognized cell adhesion molecule, and has become a major focus of academic study, as researchers believe that PSGL-1 may represent a novel area of interest in the research inquiry into the field of immune checkpoint inhibition. In this article, we review PSGL-1's structure and functions during infection and/or inflammation. We also outline a comprehensive review of its role and potential therapeutic utility during HIV-1 infection as published in contemporary academic literature.
BibTeX
@inproceedings{zaongo2021p,
  author = {Silvère D. Zaongo and Yanqiu Liu and Vijay Harypursat and Fangzhou Song and Huan Xia and Ping Ma and Yaokai Chen},
  title = {{P-Selectin Glycoprotein Ligand 1: A Potential HIV-1 Therapeutic Target}},
  booktitle = {Frontiers in Immunology},
  year = {2021},
  doi = {10.3389/fimmu.2021.710121},
}
Figure